Seed · AI
Allos AI raises $5m seed to commercialize drug reformulation platform
Oxford Science Enterprises leads Allos AI’s seed round, with Habico Invest and Berkeley SkyDeck participating.
Building the formulation and data-science teams
Allos AI announced $5 million in seed funding on January 12, 2026. Oxford Science Enterprises led the financing, with participation from Habico Invest, the Orifarm family office, and Berkeley SkyDeck.
The company plans to expand formulation development and data science as it commercializes its causal-AI platform. Its initial focus is hard-to-genericize small-molecule medicines, where changing delivery or formulation can require substantial new development work.
Funding history
Seed · This round$5M